AstraZeneca Denies Unjust Enrichment In Cancer Drug Row
AstraZeneca has doubled down on claims that it is owed unpaid royalties by U.S. drugmaker Tesaro from sales of a blockbuster cancer drug after the pharmaceutical giant was hit with a...To view the full article, register now.
Already a subscriber? Click here to view full article